Posts
The NY Times has a very interesting article on the seemingly contradictory findings on heart disease and CRP and Cholesterol.
For instance:
"Vioxx, which was pulled from the market in late September because of those risks, had been found in a study just a month earlier to cut CRP levels in half, from the danger zone to a level considered excellent. Celebrex, still on the market but linked to an increased risk of heart attack, has also been found to lower CRP levels."Why? It is probably too early to know for sure.
Why do I mention this? To remind people that our understanding of how the body works is still pretty new.
This is similar to finance where there is much contradictory research that has to be sorted through before we can say much definitively. WHich is why both fields are so interesting!
No comments:
Post a Comment